Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

rphan GPCRs. These four orphans –  GPR65/TDAG8, GPR82, MRGE and MRGF – are linked to a series of important indications, including several types of cancer and inflammatory disorders, such as asthma (GPR65/TDAG8), appetite and body weight (GPR82) and pain (MRGE and MRGF). Omeros also recently announced its ability to unlock Class B orphan GPCRs.
  • Reported positive data from its second pivotal Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery.  OMS302 met its co-primary endpoints by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period. Now with positive data from both trials in the OMS302 Phase 3 clinical program, Omeros plans to submit a New Drug Application with the U.S. Food and Drug Administration in the first half of 2013 and a Marketing Authorization Application with the European Medicines Agency in mid-2013. Omeros is building its marketing and sales capabilities in expectation of OMS302's planned commercial launch in 2014.
  • Announced promising data from the single-ascending-dose (SAD) study portion of its Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program for schizophrenia and cognitive disorders.  In this SAD study, OMS824 was well tolerated and demonstrated linear pharmacokinetics, a long half-life consistent with once daily dosing and good systemic exposure that resulted in the expected pharmacological effects in healthy subjects.  With these encouraging data, Omeros advanced OMS824 to the next stage of the Phase 1 clinical program – the evaluation of multiple-ascending dosing (MAD) of the compound.  Omeros expects to report data from this MAD trial in the near future. 
  • Completed the first Phase 3 clinical trial compar
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
    8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
    10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
    11. Celsion Corporation Announces $15 Million Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
    (Date:7/30/2014)... Toronto, Canada (PRWEB) July 30, 2014 ... been available in health services research for a ... an upswing in interest regarding the use of ... actual practice conditions. , By combining today’s powerful ... in the digital era, ‘big data’ holds significant ...
    (Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
    (Date:7/30/2014)... Yuma Regional Cancer Center Officially Opens ... comprehensive cancer care to Yuma, Arizona. , The ... has officially opened. A Mayo Clinic Care Network ... as open, semi-private and private infusion rooms, oncology ... Center, hematology, rehabilitation center, a pain management program ...
    Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
    ... and Mass Spectrometry Application Note , ... Mass Frontier , Mark R. ... Introduction , ... development. In the early discovery phase, studies are designed to help the ...
    ... , I. Introduction ... note describes assay conditions for screening GPCR agonists on a ... miniaturized platform results in low cell and reagent consumption, high ... microfluidic assay accesses test compounds from a microtiter plate and ...
    ... Mike Benway, Larry Simonson and John Ung , ... Applications Laboratory, Hopkinton, Massachusetts, USA , ... "Assay-Ready" plates prepared from compound or library stock plates in real ... to transfer and dilute 0.5μL volumes is a prerequisite for this ...
    Cached Biology Technology:Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 2Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 3Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 4Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 5Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 6Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 7Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 8Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 9Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 10HEK293 Calcium Flux Assay 2HEK293 Calcium Flux Assay 3HEK293 Calcium Flux Assay 4HEK293 Calcium Flux Assay 5Dispensing 0.5μL to "Dry" 384 Plates with the Sciclone ALH 2Dispensing 0.5μL to "Dry" 384 Plates with the Sciclone ALH 3
    (Date:7/30/2014)... a pledge of $1 million from the Cornelia Cogswell ... Neurobehavioral Biometry Center. , The newly established ... Laboratory to develop a greater breadth and depth of ... accelerating the pace of research to improve human health. ... resource for the Laboratory and its external partners, supporting ...
    (Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
    (Date:7/30/2014)... today announced an across-the-board increase in Impact Factors ... InCites Journal Citation Reports (Thomson Reuters, 2014) show ... , Essays in Biochemistry , Biochemical ... all received increases in their Impact Factors. The ... published by Portland Press Limited. , 2014 Impact ...
    Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2
    ... protein found within nerve cells are a pathological ... identified in the early 1900s by German psychiatrist and ... protein called tau cause it to aggregate in an ... tau protein is involved in the formation of microtubules, ...
    ... Within many hormone-receptor positive breast cancers lives a subpopulation ... cells with anti-estrogen drugs and you may inadvertently promote ... recently published in the Proceedings of the National ... receptor-negative cells back to a state that can be ...
    ... unique ways of hunting down a meal using their senses. ... on infrared vision, and owls take advantage of the concave ... possible prey. Leeches have not just one but two distinct ... biologists at the California Institute of Technology (Caltech), their preferred ...
    Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells 2Switching senses 2
    SAPK/JNK Antibody...
    Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
    Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
    Component in MasterPure™ Purification Kits...
    Biology Products: